Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash from Financing Activities: 2011-2024

Historic Cash from Financing Activities for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to -$58.3 million.

  • Adma Biologics' Cash from Financing Activities fell 9.26% to -$27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$65.9 million, marking a year-over-year increase of 0.51%. This contributed to the annual value of -$58.3 million for FY2024, which is 49.53% down from last year.
  • As of FY2024, Adma Biologics' Cash from Financing Activities stood at -$58.3 million, which was down 49.53% from -$39.0 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Cash from Financing Activities registered a high of $143.9 million during FY2020, and its lowest value of -$58.3 million during FY2024.
  • For the 3-year period, Adma Biologics' Cash from Financing Activities averaged around $3.9 million, with its median value being -$39.0 million (2023).
  • Data for Adma Biologics' Cash from Financing Activities shows a maximum YoY tumbled of 135.82% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Adma Biologics' Cash from Financing Activities stood at $143.9 million in 2020, then declined by 15.88% to $121.0 million in 2021, then decreased by 10.08% to $108.9 million in 2022, then plummeted by 135.82% to -$39.0 million in 2023, then slumped by 49.53% to -$58.3 million in 2024.